Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4125714
Max Phase: Preclinical
Molecular Formula: C37H45N9O10
Molecular Weight: 775.82
Molecule Type: Small molecule
Associated Items:
ID: ALA4125714
Max Phase: Preclinical
Molecular Formula: C37H45N9O10
Molecular Weight: 775.82
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(CCCCCCC(=O)N/N=C/c1ccc(OCCOCCOCCn2cc(CNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)nn2)cc1)NO
Standard InChI: InChI=1S/C37H45N9O10/c47-31-15-14-30(35(50)40-31)46-36(51)28-6-5-7-29(34(28)37(46)52)38-23-26-24-45(44-41-26)16-17-54-18-19-55-20-21-56-27-12-10-25(11-13-27)22-39-42-32(48)8-3-1-2-4-9-33(49)43-53/h5-7,10-13,22,24,30,38,53H,1-4,8-9,14-21,23H2,(H,42,48)(H,43,49)(H,40,47,50)/b39-22+
Standard InChI Key: MHILTYZXXFOWJH-WVKHYPTHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 775.82 | Molecular Weight (Monoisotopic): 775.3289 | AlogP: 1.70 | #Rotatable Bonds: 23 |
Polar Surface Area: 244.77 | Molecular Species: NEUTRAL | HBA: 15 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 19 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 8.91 | CX Basic pKa: 1.95 | CX LogP: 1.47 | CX LogD: 1.46 |
Aromatic Rings: 3 | Heavy Atoms: 56 | QED Weighted: 0.03 | Np Likeness Score: -1.12 |
1. Yang K, Song Y, Xie H, Wu H, Wu YT, Leisten ED, Tang W.. (2018) Development of the first small molecule histone deacetylase 6 (HDAC6) degraders., 28 (14): [PMID:29871848] [10.1016/j.bmcl.2018.05.057] |
2. Wu H, Yang K, Zhang Z, Leisten ED, Li Z, Xie H, Liu J, Smith KA, Novakova Z, Barinka C, Tang W.. (2019) Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity., 62 (15): [PMID:31271281] [10.1021/acs.jmedchem.9b00516] |
Source(1):